3/26
05:49 am
sldb
Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".
3/25
10:56 am
sldb
Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.
Low
Report
Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.
3/23
08:04 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
3/20
08:44 am
sldb
Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.
3/20
08:26 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
3/20
08:05 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.
3/19
04:55 pm
sldb
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/19
04:45 pm
sldb
Solid Biosciences GAAP EPS of -$0.53 misses by $0.02 [Seeking Alpha]
Low
Report
Solid Biosciences GAAP EPS of -$0.53 misses by $0.02 [Seeking Alpha]
3/19
04:12 pm
sldb
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Low
Report
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
3/12
08:05 pm
sldb
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Medium
Report
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/12
03:07 pm
sldb
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start [Seeking Alpha]
Low
Report
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start [Seeking Alpha]
3/12
01:36 pm
sldb
Solid Biosciences says interim results reinforce confidence in SGT-003 potential [Yahoo! Finance]
Low
Report
Solid Biosciences says interim results reinforce confidence in SGT-003 potential [Yahoo! Finance]
3/12
08:44 am
sldb
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
3/11
01:31 pm
sldb
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial [Yahoo! Finance]
Medium
Report
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial [Yahoo! Finance]
3/11
01:01 pm
sldb
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
Low
Report
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
3/11
09:03 am
sldb
Solid Biosciences (SLDB) had its "outperform" rating reaffirmed by Wedbush. They now have a $14.00 price target on the stock.
Medium
Report
Solid Biosciences (SLDB) had its "outperform" rating reaffirmed by Wedbush. They now have a $14.00 price target on the stock.
3/6
08:51 am
sldb
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference [Yahoo! Finance]
Medium
Report
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference [Yahoo! Finance]
3/6
08:31 am
sldb
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
High
Report
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
3/6
08:30 am
sldb
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
High
Report
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
3/2
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/13
06:25 pm
sldb
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
High
Report
Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
2/9
06:35 pm
sldb
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones [Seeking Alpha]
Low
Report
Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones [Seeking Alpha]
2/9
12:27 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Low
Report
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
2/9
08:00 am
sldb
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
Medium
Report
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
2/6
08:22 am
sldb
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]